Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings - Twist Bioscience (NASDAQ:TWST)

Core Insights - Twist Bioscience Corporation is set to release its fourth-quarter earnings on November 14, with analysts predicting a loss of 50 cents per share, an improvement from a loss of 59 cents per share in the same quarter last year [1] - The expected quarterly revenue for Twist Bioscience is $97.36 million, which represents an increase from $84.71 million year-over-year [1] - The company issued FY25 sales guidance that fell below market estimates on August 4 [1] Stock Performance - Shares of Twist Bioscience declined by 6.2%, closing at $29.90 on Thursday [2] Analyst Ratings - Stephens & Co. analyst Steven Etoch initiated coverage with an Overweight rating and a price target of $41 [6] - Goldman Sachs analyst Matthew Sykes maintained a Buy rating but reduced the price target from $55 to $48 [6] - Guggenheim analyst Subbu Nambi reiterated a Buy rating with a price target of $50 [6] - Baird analyst Catherine Ramsey maintained an Outperform rating and lowered the price target from $54 to $44 [6] - JP Morgan analyst Rachel Vatnsdal maintained an Underweight rating and cut the price target from $40 to $33 [6]